Robert Chong

David Geffen School of Medicine

H指数:13

被引数:1,195

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab

扩散直方图分析预测接受贝伐珠单抗治疗的对比增强型IDH突变型胶质瘤的无进展生存期

Journal of Neuro-Oncology

IF3.1

2026-09-090

OAAI

Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial

新辅助PD1联合CTLA-4免疫检查点阻断在可手术切除的复发性胶质母细胞瘤中的应用：一项随机手术窗口期试验

Nature Communications

IF15.7

2026-09-050

Lu Sun; Lauren F. Markus; Julio C. Sanchez; Thomas J. Lai; Eudocia Quant Lee; Gang Li; Jiyoon Kim; Zian Zhuang; Brenda Acevedo; Richard G. Everson; Ingo K. Mellinghoff; Elisa Aquilanti; L. Nicolas Gonzalez Castro; J. Ricardo McFaline-Figueroa; Lakshmi Nayak; Rameen Beroukhim; Robert A. Chong; Jacqueline Stone; Thomas Kaley; Lauren Schaff; Jessica Wilcox; Catharina Westergaard; Alyssa Russ; Maria Lavallee; Ugonma Chukwueke; Annick D. Van den Abbeele; Michael Lim; Benjamin M. Ellingson; David A. Reardon; Timothy F. Cloughesy; Robert M. Prins; Patrick Y. Wen

MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy

MGMT通过CRISPR/Cas13 RNA引导的RNA靶向下调可增强胶质瘤细胞对替莫唑胺化疗的敏感性

Journal of Neuro-Oncology

IF3.1

2026-03-120

OAAI

A single-institution Retrospective Study of Multicentric Gliomas Stratified by IDH Mutational Status

单机构基于IDH突变状态分层的多中心胶质瘤回顾性研究

Neuro-Oncology Advances

IF4.1

2026-02-270

CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES

CTIM-12. 双免疫检查点阻断治疗可手术切除的复发性胶质母细胞瘤：临床与分子结局

Neuro-Oncology

IF13.4

2025-11-110

Toxicity Phenotyping for Glioblastoma: Clinical and Molecular Determinants of Temozolomide Treatment Disruption

胶质母细胞瘤的毒性表型：替莫唑胺治疗中断的临床与分子决定因素

NEURO-ONCOLOGY

IF13.4

2025-11-010

PRE

Corticosteroid-induced contrast-enhancing volume shrinkage and apparent diffusion coefficient reduction in glioblastoma MRI

糖皮质激素诱导的对比增强体积缩小和表观扩散系数降低在胶质母细胞瘤MRI中

NEURO-ONCOLOGY

IF13.4

2025-11-010

OAAI

A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma

NEURO-ONCOLOGY ADVANCES

IF4.1

2025-02-190

OAAI

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma

EGFRvIII x CD3 双特异性抗体在 newly diagnosed glioblastoma 治疗中的首次人体研究

NEURO-ONCOLOGY ADVANCES

IF4.1

2025-01-011

OAAI

Whittle, James R.; Vieito, Maria; Rohrberg, Kristoffer; Rodriguez-Ruiz, Maria E.; Castanon, Eduardo; Mellinghoff, Ingo K.; Van Linde, Myra; Cloughesy, Timothy; Reardon, David A.; Chong, Robert A.; Rosenthal, Mark; Wick, Antje; Waldhauer, Inja; Henkel, Nina; Romagnoli, Barbara; Wolowski, Vincent; Dey, Shuva; Heil, Florian; Heichinger, Christian; Flinn, Nick; Gou, Jean-Philippe; Smith, Lance; Prince, Frederic; Derks, Michael; Roller, Andreas; Schiff, Christina; Schneider, Meike; Mason, Warren

A PHASE 1 STUDY OF ERAS-801, A POTENT, SELECTIVE, AND CENTRAL NERVOUS SYSTEM (CNS)-PENETRANT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR, FOR PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)

NEURO-ONCOLOGY

IF13.4

2024-11-110

PRE

A PHASE 1, SAFETY LEAD-IN AND RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF VORASIDENIB COMBINED WITH PEMBROLIZUMAB IN RECURRENT OR PROGRESSIVE ENHANCING IDH-1 MUTANT GLIOMA: TRIAL IN PROGRESS

NEURO-ONCOLOGY

IF13.4

2024-11-110

PRE

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients

NEURO-ONCOLOGY ADVANCES